

Prozac FUM1 Pharmaco-toxicological studies in juvenile rats - response to LoQ

Reply Reply All Forward

Thu 22/01/2009 13:48

090122_Cover letter response to LoQ.pdf 28 KB
090122_Response to LoQ FINAL.pdf 118 KB

Dear both,

Please find Lilly's response to the List of Questions in the Final Joint Assessment Report attached.

The response is also being couriered to you today.

Regards,

[Redacted signature]

Lilly UK
Eri Wood Manor
Windlesham, Surrey, GU20 6PH
UNITED KINGDOM

www.lilly.co.uk



CONFIDENTIALITY NOTICE: This e-mail message from Lilly UK (including all attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message. E-mail is susceptible to data corruption, interception, unauthorized amendment, tampering and viruses, and we only send and receive e-mails on the basis that we are not liable for any such corruption, interception, amendment, tampering or viruses or any consequences thereof.

This email was received from the INTERNET and scanned by the Government Secure Intranet anti-virus service supplied by Cable&Wireless in partnership with MessageLabs. (CCTM Certificate Number 2007/11/0032.) In case of problems, please call your organisation's IT Helpdesk. Communications via the GSi may be automatically logged, monitored and/or recorded for legal purposes.